A股異動丨國藥股份(600511.SH)創歷史新高 新冠滅活疫苗阿聯酋獲批上市 數據顯示有效率達86%
格隆匯12月10日丨國藥股份(600511.SH)漲4.48%,報57.15元,刷新了2015年牛市歷史最高點,總市值431億元。據阿聯酋通訊社,該國衞生和預防部今天宣佈對國藥集團中國生物北京生物製品研究所研發的新冠病毒滅活疫苗在該國進行註冊。這一決定是應此前中國國藥集團下屬的中國生物製藥有限公司(國藥中生)提出的申請而做出的迴應。阿聯酋衞生和預防部與阿布扎比衞生部還對國藥中生提交的三期臨牀試驗數據進行了複核。這一對持有125個不同國籍的約3.1萬名志願者進行的臨牀實驗顯示,這款中國生產的新冠病毒滅活疫苗對抗病毒感染的有效性為86%,中和抗體轉陽率為99%,能100%預防中度和重度的新冠肺炎病例。而且相關研究沒有發現疫苗存在嚴重的安全隱患。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.